Remarks

No new matter has been added. The specification has been amended to direct the entry of this sequence listing after the claims of the above identified application and to provide the SEQ ID NO's next to the specific sequence.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

Applicants respectfully request that the Sequence Listing submitted herewith be introduced into the captioned application.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

Date: September 14, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version of Amendment With Markings to Show Changes Made

In the Specification:

The paragraph starting on page 5, line 10, and ending on page 5, line 21:

> The invention comprises a compound selected from the group consisting of:
>
> (A) GLP-1(7-36) peptide comprising the sequence:
> His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
> Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
> Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
> Lys-Gly-Arg (SEQ ID NO:2)
>
> and
>
> (B) a derivative of such peptide;
>
> wherein the compound is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1(1-36) or GLP-1(1-37).

The paragraph starting on page 5, line 22, and ending on page 6, line 9:

> The invention also includes a compound selected from the group consisting of:
>
> (A) GLP-1(7-36) peptide comprising the sequence:
> His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
> Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
> Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
> Lys-Gly-Arg (SEQ ID NO:2)
>
> and
>
> (B) a derivative of such peptide;
>
> wherein the compound is substantially free of natural contaminants, and has an insulinotropic activity at a concentration of at least 10^{-10} M.

The paragraph starting on page 6, line 10, and ending on page 7, line 2:

> Of particular interest are GLP-1(7-36) peptides of the following formula:
>
> (1) H_2N-X-CO-R^1
> wherein R^1 is OH, OM, or -NR^2R^3;
> M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group;

R^2 and R^3 are the same or different and selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group;

X is a GLP-1(7-36) peptide comprising the sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg (SEQ ID NO:2);

NH_2 is the amine group of the amino terminus of X; and

CO is the carbonyl group of the carboxy terminus of X and where the naturally processed form is arginineamide at position 36 of GLP-1(7-36);

(2) the acid addition salts thereof; and

(3) the protected or partially protected derivatives thereof;

wherein such compound has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1(1-36) or GLP-1(1-37).

The paragraph starting on page 7, line 12, and ending on page 7, line 14:

Figure 1 shows the DNA structure (SEQ ID NO:1) and corresponding amino acid sequence (SEQ ID NO:2) of rat preproglucagon. The preproglucagon precursor is proteolytically cleaved at sites indicated by circles.

The Sequence Listing is added at the end of the application.